Literature DB >> 35249974

Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results.

Maria Demarco1, Didem Egemen1, Noorie Hyun1, Xiaojian Chen1, Anna-Barbara Moscicki2, Li Cheung1, Olivia Carter-Pokras1, Anne Hammer3, Julia C Gage1, Megan A Clarke1, Philip E Castle1, Brian Befano1, Jie Chen1, Cher Dallal1, Xin He1, Kanan Desai1, Thomas Lorey4, Nancy Poitras4, Tina R Raine-Bennett4, Rebecca B Perkins5, Nicolas Wentzensen1, Mark Schiffman1.   

Abstract

OBJECTIVE: The US screening and management guidelines for cervical cancer are based on the absolute risk of precancer estimated from large clinical cohorts and trials. Given the widespread transition toward screening with human papillomavirus (HPV) testing, it is important to assess which additional factors to include in clinical risk assessment to optimize management of HPV-infected women.
MATERIALS AND METHODS: We analyzed data from HPV-infected women, ages 30-65 years, in the National Cancer Institute-Kaiser Permanente Northern California Persistence and Progression study. We estimated the influence of HPV risk group, cytology result, and selected cofactors on immediate risk of cervical intraepithelial neoplasia grade 3 or higher (CIN 3+) among 16,094 HPV-positive women. Cofactors considered included, age, race/ethnicity, income, smoking, and hormonal contraceptive use.
RESULTS: Human papillomavirus risk group and cytology test result were strongly correlated with CIN 3+ risk. After considering cytology and HPV risk group, other cofactors (age, race/ethnicity, income, smoking, and hormonal contraceptive use) had minimal impact on CIN 3+ risk and did not change recommended management based on accepted risk thresholds. We had insufficient data to assess the impact of long-duration heavy smoking, parity, history of sexually transmitted infection, or immunosuppression.
CONCLUSIONS: In our study at the Kaiser Permanente Northern California, the risk of CIN 3+ was determined mainly by HPV risk group and cytology results, with other cofactors having limited impact in adjusted analyses. This supports the use of HPV and cytology results in risk-based management guidelines.
Copyright © 2022, ASCCP.

Entities:  

Mesh:

Year:  2022        PMID: 35249974      PMCID: PMC8940696          DOI: 10.1097/LGT.0000000000000667

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   3.842


  28 in total

1.  How does tobacco smoke contribute to cervical carcinogenesis?

Authors:  Philip E Castle
Journal:  J Virol       Date:  2008-06       Impact factor: 5.103

2.  Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.

Authors:  P Appleby; V Beral; A Berrington de González; D Colin; S Franceschi; A Goodill; J Green; J Peto; M Plummer; S Sweetland
Journal:  Int J Cancer       Date:  2006-03-15       Impact factor: 7.396

3.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Authors:  L Stewart Massad; Mark H Einstein; Warner K Huh; Hormuzd A Katki; Walter K Kinney; Mark Schiffman; Diane Solomon; Nicolas Wentzensen; Herschel W Lawson
Journal:  Obstet Gynecol       Date:  2013-04       Impact factor: 7.661

Review 4.  Cervical cancer and use of hormonal contraceptives: a systematic review.

Authors:  Jennifer S Smith; Jane Green; Amy Berrington de Gonzalez; Paul Appleby; Julian Peto; Martyn Plummer; Silvia Franceschi; Valerie Beral
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.

Authors:  Philip E Castle; Xianhong Xie; Xiaonan Xue; Nancy E Poitras; Thomas S Lorey; Walter K Kinney; Nicolas Wentzensen; Howard D Strickler; Emily A Burger; Mark Schiffman
Journal:  Prev Med       Date:  2018-10-11       Impact factor: 4.018

6.  Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.

Authors:  Philip E Castle; Ruth Shaber; Brandon J LaMere; Walter Kinney; Barbara Fetterma; Nancy Poitras; Thomas Lorey; Mark Schiffman; Anne Dunne; Janae M Ostolaza; Sharod McKinney; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-17       Impact factor: 4.254

7.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

8.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

Authors:  Rebecca B Perkins; Richard S Guido; Philip E Castle; David Chelmow; Mark H Einstein; Francisco Garcia; Warner K Huh; Jane J Kim; Anna-Barbara Moscicki; Ritu Nayar; Mona Saraiya; George F Sawaya; Nicolas Wentzensen; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 1.925

9.  Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study.

Authors:  W A Poppe; P S Ide; M P Drijkoningen; J M Lauweryns; F A Van Assche
Journal:  Gynecol Obstet Invest       Date:  1995       Impact factor: 2.031

10.  HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica.

Authors:  A Hildesheim; R Herrero; P E Castle; S Wacholder; M C Bratti; M E Sherman; A T Lorincz; R D Burk; J Morales; A C Rodriguez; K Helgesen; M Alfaro; M Hutchinson; I Balmaceda; M Greenberg; M Schiffman
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.